Effect of Nasal Carriage of Species on COVID-19 Severity: a Cross-sectional Study

Overview

Journal Microbiol Spectr

Specialty Microbiology

Date 2024 Jan 9

PMID 38193730

Authors

Muinah A Fowora

Adenike Aiyedogbon

Ibilola Omolopo

Ahmed O Tajudeen

Abdul-Lateef Olanlege

Adefunke Abioye

Grace B Akintunde

Babatunde L Salako

Affiliations

Soon will be listed here.

Abstract

Intranasal sprays containing species are being researched for treating viral respiratory tract infections. The aim of this study was to assess the relationship between the nasal carriage of and COVID-19 severity. This was a cross-sectional study that collected nasopharyngeal samples from adults 18 years and above visiting two COVID-19 testing centers in Lagos, Nigeria, between September 2020 and September 2021. species were cultured from the samples and confirmed using 16 s rRNA gene sequencing. The dependent variable was COVID-19 status classified as negative, asymptomatic, mild, or severe. The independent variable was the nasal carriage of species. Multinomial regression analysis was done to determine the association between nasal carriage of and COVID-19 severity after adjusting for age, sex, and co-morbidity status. A total of 388 participants were included in the study with mean (standard deviation) age of 40.05 (13.563) years. Sixty-one percent of the participants were male, 100 (25.8%) had severe COVID-19, 130 (33.5%) had pre-existing comorbidity, and 76 (19.6%) had cultured from their nasopharyngeal specimen. species presence was significantly associated with higher odds of severe COVID-19 compared to having a negative COVID-19 status (AOR = 3.347, 95% CI: 1.359, 8.243). However, the presence of species was significantly associated with lower odds of severe COVID-19 compared to having a mild COVID-19 status. The study suggests that nasal carriage of species is associated with the clinical course of COVID-19 and supports the exploration of species in the management of viral respiratory tract infections.IMPORTANCEWith the introduction of intranasal spray containing species for the treatment of viral respiratory tract infections, such as COVID-19 and respiratory syncytial virus, identifying the association between the nasal carriage of species and COVID-19 susceptibility and severity will help further substantiate the investigation of these bacteria for COVID-19 prevention and treatment. This study evaluated the association between the carriage of species in the nasopharyngeal tract and COVID-19 severity and found that the presence of species in the nasopharynx may significantly impact the clinical course of COVID-19.

References

Erinoso O, Wright K, Anya S, Bowale A, Adejumo O, Adesola S . Clinical characteristics, predictors of symptomatic coronavirus disease 2019 and duration of hospitalisation in a cohort of 632 Patients in Lagos State, Nigeria. Niger Postgrad Med J. 2020; 27(4):285-292. DOI: 10.4103/npmj.npmj_272_20. View

Yang Y, Jing Y, Yang J, Yang Q . Effects of intranasal administration with on immune cells in the nasal mucosa and tonsils of piglets. Exp Ther Med. 2018; 15(6):5189-5198. PMC: 5958783. DOI: 10.3892/etm.2018.6093. View

Lansbury L, Lim B, Baskaran V, Lim W . Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020; 81(2):266-275. PMC: 7255350. DOI: 10.1016/j.jinf.2020.05.046. View

Liu J, Liu S, Zhang Z, Lee X, Wu W, Huang Z . Association between the nasopharyngeal microbiome and metabolome in patients with COVID-19. Synth Syst Biotechnol. 2021; 6(3):135-143. PMC: 8200311. DOI: 10.1016/j.synbio.2021.06.002. View

Bahceci I, Yildiz I, Duran O, Soztanaci U, Kirdi Harbawi Z, Senol F . Secondary Bacterial Infection Rates Among Patients With COVID-19. Cureus. 2022; 14(2):e22363. PMC: 8938257. DOI: 10.7759/cureus.22363. View

Reva O, Sorokulova I, Smirnov V . Simplified technique for identification of the aerobic spore-forming bacteria by phenotype. Int J Syst Evol Microbiol. 2001; 51(Pt 4):1361-1371. DOI: 10.1099/00207713-51-4-1361. View

Goto K, Omura T, Hara Y, Sadaie Y . Application of the partial 16S rDNA sequence as an index for rapid identification of species in the genus Bacillus. J Gen Appl Microbiol. 2002; 46(1):1-8. DOI: 10.2323/jgam.46.1. View

Onyegbutulem H, Dogo D, Nnabuchi C, Aghahowa M, Alu F, Afiomah E . Epidemiologic Characteristics, Clinical Features and Outcomes of COVID 19: Patients Admitted at the Asokoro District Hospital Isolation and Treatment Center, Abuja, North Central Nigeria. West Afr J Med. 2021; Vol. 38(11):1120-1128. View

Sandrin C, Peypoux F, Michel G . Coproduction of surfactin and iturin A, lipopeptides with surfactant and antifungal properties, by Bacillus subtilis. Biotechnol Appl Biochem. 1990; 12(4):370-5. View

10.

De Boeck I, Cauwenberghs E, Spacova I, Gehrmann T, Eilers T, Delanghe L . Randomized, Double-Blind, Placebo-Controlled Trial of a Throat Spray with Selected Lactobacilli in COVID-19 Outpatients. Microbiol Spectr. 2022; 10(5):e0168222. PMC: 9604152. DOI: 10.1128/spectrum.01682-22. View

11.

Musuuza J, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N . Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. PLoS One. 2021; 16(5):e0251170. PMC: 8101968. DOI: 10.1371/journal.pone.0251170. View

12.

De Maio F, Posteraro B, Ponziani F, Cattani P, Gasbarrini A, Sanguinetti M . Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients. Biol Proced Online. 2020; 22:18. PMC: 7382556. DOI: 10.1186/s12575-020-00131-7. View

13.

Shoaib N, Noureen N, Munir R, Shah F, Ishtiaq N, Jamil N . COVID-19 severity: Studying the clinical and demographic risk factors for adverse outcomes. PLoS One. 2021; 16(8):e0255999. PMC: 8357125. DOI: 10.1371/journal.pone.0255999. View

14.

Chroneos Z, Sever-Chroneos Z, Shepherd V . Pulmonary surfactant: an immunological perspective. Cell Physiol Biochem. 2010; 25(1):13-26. PMC: 3025886. DOI: 10.1159/000272047. View

15.

Theatre A, Cano-Prieto C, Bartolini M, Laurin Y, Deleu M, Niehren J . The Surfactin-Like Lipopeptides From spp.: Natural Biodiversity and Synthetic Biology for a Broader Application Range. Front Bioeng Biotechnol. 2021; 9:623701. PMC: 7960918. DOI: 10.3389/fbioe.2021.623701. View

16.

Brugger S, Bomar L, Lemon K . Commensal-Pathogen Interactions along the Human Nasal Passages. PLoS Pathog. 2016; 12(7):e1005633. PMC: 4936728. DOI: 10.1371/journal.ppat.1005633. View

17.

Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P . Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020; 383(16):1522-1534. PMC: 7315890. DOI: 10.1056/NEJMoa2020283. View

18.

Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O . Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PLoS One. 2021; 16(3):e0248281. PMC: 7959379. DOI: 10.1371/journal.pone.0248281. View

19.

Jochems S, Ferreira D, Smits H . Microbiota and compartment matter in the COVID-19 response. Nat Immunol. 2021; 22(11):1350-1352. DOI: 10.1038/s41590-021-01041-w. View

20.

Roberts M, Nakamura L, Cohan F . Bacillus mojavensis sp. nov., distinguishable from Bacillus subtilis by sexual isolation, divergence in DNA sequence, and differences in fatty acid composition. Int J Syst Bacteriol. 1994; 44(2):256-64. DOI: 10.1099/00207713-44-2-256. View